Literature DB >> 2694416

Ocular complications of systemic cancer chemotherapy.

P S Imperia1, H M Lazarus, J H Lass.   

Abstract

Cancer chemotherapy has changed rapidly in recent years. New agents are constantly being developed. Established agents are being used with increased frequency, in new combinations, at higher dosages, and via new routes of administration. Enhanced survival, as well as increased drug toxicity, has resulted. Ocular toxicity is not uncommon and can greatly impact on quality of life. Practitioners in all fields are increasingly caring for patients who are receiving cancer chemotherapy. The recognition of eye disease resulting from chemotherapy is essential to appropriate patient management. We provide a review of the rapidly growing body of literature on the ocular toxicity of systemic cancer chemotherapy with particular attention to context, clinical course, mechanism, prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2694416     DOI: 10.1016/0039-6257(89)90105-7

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  16 in total

1.  Clinical features and treatment outcomes of patients with tearing after chemotherapy.

Authors:  Jinhwan Park; Joohyun Kim; Sehyun Baek
Journal:  Eye (Lond)       Date:  2018-12-10       Impact factor: 3.775

2.  Anterior visual system involvement in non-Hodgkin's lymphoma.

Authors:  A G Zaman; E M Graham; M D Sanders
Journal:  Br J Ophthalmol       Date:  1993-03       Impact factor: 4.638

3.  Visual failure and optic atrophy associated with chlorambucil therapy.

Authors:  P H Yiannakis; A J Larner
Journal:  BMJ       Date:  1993-01-09

4.  Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.

Authors:  R B Raffa; R J Tallarida
Journal:  J Clin Pharm Ther       Date:  2010-06       Impact factor: 2.512

5.  Tamoxifen therapy conveys increased risk of developing a macular hole.

Authors:  Brendan G Cronin; Christopher K Lekich; Robert D Bourke
Journal:  Int Ophthalmol       Date:  2006-09-15       Impact factor: 2.031

6.  Visual field defects during low-dose methotrexate therapy.

Authors:  B A Johansson
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

Review 7.  Supportive cryotherapy: a review from head to toe.

Authors:  Kunal C Kadakia; Shaina A Rozell; Anish A Butala; Charles L Loprinzi
Journal:  J Pain Symptom Manage       Date:  2013-11-07       Impact factor: 3.612

8.  Oxaliplatin-Related Ocular Toxicity.

Authors:  Marina Mesquida; Bernardo Sanchez-Dalmau; Santiago Ortiz-Perez; Laura Pelegrín; Juan José Molina-Fernandez; Marc Figueras-Roca; Ricardo Casaroli-Marano; Alfredo Adán
Journal:  Case Rep Oncol       Date:  2010-11-22

Review 9.  Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature.

Authors:  H M Brink; L V Beex
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

10.  Ischaemic retinopathy occurring in patients receiving bone marrow allografts and campath-1G: a clinicopathological study.

Authors:  A R Webster; J R Anderson; E M Richards; A T Moore
Journal:  Br J Ophthalmol       Date:  1995-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.